Park SR - Search Results

1

Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach.

Kurokawa Y, Yang HK, Cho H, Ryu MH, Masuzawa T, Park SR, Matsumoto S, Lee HJ, Honda H, Kwon OK, Ishikawa T, Lee KH, Nabeshima K, Kong SH, Shimokawa T, Yook JH, Doki Y, Im SA, Hirota S, Hahn S, Nishida T, Kang YK. Kurokawa Y, et al. Among authors: park sr. Br J Cancer. 2017 Jun 27;117(1):25-32. doi: 10.1038/bjc.2017.144. Epub 2017 May 23. Br J Cancer. 2017. PMID: 28535156 Free PMC article. Clinical Trial.

2

A multi-center, late phase II clinical trial of Genexol (paclitaxel) and cisplatin for patients with advanced gastric cancer.

Park SR, Oh DY, Kim DW, Kim TY, Heo DS, Bang YJ, Kim NK, Kang WK, Kim HT, Im SA, Suh JH, Kim HK, Kim HK. Park SR, et al. Oncol Rep. 2004 Nov;12(5):1059-64. Oncol Rep. 2004. PMID: 15492793 Clinical Trial.

3

Pemetrexed and cisplatin in patients with advanced gastric cancer: a Korean cancer study group multicenter phase II study.

Kim YH, Chung HC, Kang WK, Park SR, Kim CS, Kim TY, Shin SW, Park BJ, Cha SJ, Bang YJ. Kim YH, et al. Among authors: park sr, park bj. Cancer Chemother Pharmacol. 2008 Jul;62(2):263-70. doi: 10.1007/s00280-007-0600-y. Epub 2007 Oct 25. Cancer Chemother Pharmacol. 2008. PMID: 17960386 Clinical Trial.

4

Endoscopic ultrasound and computed tomography in restaging and predicting prognosis after neoadjuvant chemotherapy in patients with locally advanced gastric cancer.

Park SR, Lee JS, Kim CG, Kim HK, Kook MC, Kim YW, Ryu KW, Lee JH, Bae JM, Choi IJ. Park SR, et al. Cancer. 2008 Jun;112(11):2368-76. doi: 10.1002/cncr.23483. Cancer. 2008. PMID: 18404697 Free article. Clinical Trial.

5

Epidermal growth factor receptor intron 1 CA dinucleotide repeat polymorphism and survival of advanced gastric cancer patients treated with cetuximab plus modified FOLFOX6.

Han SW, Oh DY, Im SA, Park SR, Lee KW, Song HS, Lee NS, Lee KH, Choi IS, Lee MH, Kim MA, Kim WH, Bang YJ, Kim TY. Han SW, et al. Among authors: park sr. Cancer Sci. 2010 Mar;101(3):793-9. doi: 10.1111/j.1349-7006.2009.01447.x. Epub 2009 Nov 23. Cancer Sci. 2010. PMID: 20047592 Free article. Clinical Trial.

6

Clinical characteristics and treatment outcomes of gastric cancer patients with isolated para-aortic lymph node involvement.

Park IH, Kim SY, Kim YW, Ryu KW, Lee JH, Lee JS, Park YI, Kim NK, Park SR. Park IH, et al. Among authors: park yi, park sr. Cancer Chemother Pharmacol. 2011 Jan;67(1):127-36. doi: 10.1007/s00280-010-1296-y. Epub 2010 Mar 11. Cancer Chemother Pharmacol. 2011. PMID: 20221601

7

Open-label, randomized comparison of the efficacy of intravenous dolasetron mesylate and ondansetron in the prevention of acute and delayed cisplatin-induced emesis in cancer patients.

Kim JS, Baek JY, Park SR, Choi IS, Kim SI, Kim DW, Im SA, Kim TY, Heo DS, Bang YJ, Kim NK. Kim JS, et al. Among authors: park sr. Cancer Res Treat. 2004 Dec;36(6):372-6. doi: 10.4143/crt.2004.36.6.372. Epub 2004 Dec 31. Cancer Res Treat. 2004. PMID: 20368831 Free PMC article.

8

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study.

Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, Lim HY, Yamada Y, Wu J, Langer B, Starnawski M, Kang YK. Ohtsu A, et al. Among authors: park sr. J Clin Oncol. 2011 Oct 20;29(30):3968-76. doi: 10.1200/JCO.2011.36.2236. Epub 2011 Aug 15. J Clin Oncol. 2011. PMID: 21844504 Clinical Trial.

9

Two-year adjuvant imatinib mesylate after complete resection of localized, high-risk GIST with KIT exon 11 mutation.

Kang YK, Kang BW, Im SA, Lee JL, Park SR, Kang WK, Chang HM, Kim TW, Oh DY, Jung KH, Ryu MH. Kang YK, et al. Among authors: park sr. Cancer Chemother Pharmacol. 2013 Jan;71(1):43-51. doi: 10.1007/s00280-012-1970-3. Epub 2012 Oct 7. Cancer Chemother Pharmacol. 2013. PMID: 23053257 Clinical Trial.

10

Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer.

Park SR, Hong YS, Lim HS, Seong MW, Kong SY, Kim SY, Park YI, Jung KH. Park SR, et al. Among authors: park yi. Cancer Chemother Pharmacol. 2013 Nov;72(5):953-64. doi: 10.1007/s00280-013-2272-0. Epub 2013 Aug 28. Cancer Chemother Pharmacol. 2013. PMID: 23982118 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

698 results

Search Page